Traci M. Poole, PharmD, BCACP, BCGP, FAPhA

The pharmacists expressed a hopeful look toward the future of RSV immunization, expressing optimism about increasing vaccine uptake, expanding protection across populations, and the potential for new developments on the horizon.

The panel examined the evolving reimbursement landscape for RSV vaccines, with a focus on the positive impact of the Inflation Reduction Act for Medicare Part D beneficiaries.

The panel discussed the expected side effects associated with RSV immunization, including common local reactions like pain and swelling at the injection site, as well as systemic effects such as fatigue, fever, and muscle aches.

The panel examined practical strategies for coadministering respiratory syncytial virus vaccines with those for other respiratory illnesses, such as flu and COVID-19.

The panel examined practical strategies for following up with vaccine-hesitant patients, emphasizing the critical role of health information technology in this process.

The panelists examined how the experience of vaccine mandates during COVID-19 fostered a lasting sense of distrust and resistance, with misinformation exploiting fear of making the wrong choice for oneself or one's child.

The pharmacists examined the intersection of RSV prevention and antimicrobial stewardship, sparked by data showing that RSV drives more antibiotic prescribing than any other viral infection in children.

The panelists examined survey data revealing that approximately 40% of mothers with infants entering their first RSV season in 2025 expressed uncertainty or reluctance about administering the monoclonal antibody to their newborns.

The panelists examined the compelling new data showing a 30% reduction in RSV-associated hospitalizations for infants under 8 months and a striking 50% drop for those under 2 months, directly attributable to the introduction of maternal vaccination and monoclonal antibodies.

The panel examined the significant expansion of the Vaccines for Children (VFC) program to over 1000 birthing hospitals, now covering approximately 42% of US births and enabling broader access to respiratory syncytial virus immunizations for newborns.

The expert pharmacists examined the real-world administration errors that have emerged from having multiple respiratory syncytial virus vaccine options with different indications.

The expert pharmacists examined recent shifts in adult respiratory syncytial virus vaccination recommendations, clarifying that all adults 75 years or older should receive the vaccine, and that those aged 50 to 74 years with certain high-risk conditions are also eligible.

The expert pharmacists examined the critical importance of timing in RSV immunization for pregnant individuals and infants, noting that patient conversations often fall at opposite ends of the spectrum, from eager acceptance to strong resistance.

RSV drives massive U.S. healthcare costs, with hospitalizations fueling most expenses; learn why prevention, vaccines, and antibodies protect adults, infants, and families.

Pharmacist experts explain RSV seasonality, symptoms and high-risk groups, then share practical strategies to close immunization gaps and streamline vaccine delivery.